img

Global and United States Innovative Biologics and Biosimilars Market Report & Forecast 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and United States Innovative Biologics and Biosimilars Market Report & Forecast 2024-2034

Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
Market Analysis and InsightsGlobal and United States Innovative Biologics and Biosimilars Market
This report focuses on global and United States Innovative Biologics and Biosimilars market, also covers the segmentation data of other regions in regional level and county level.
The global Innovative Biologics and Biosimilars revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the review period (2024-2034).
In United States the Innovative Biologics and Biosimilars revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period 2024-2034.
The global key players of Innovative Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. The global five biggest players hold a share of % in 2024.
Global Innovative Biologics and Biosimilars Scope and Market Size
Innovative Biologics and Biosimilars market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Innovative Biologics and Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2034.
For United States market, this report focuses on the Innovative Biologics and Biosimilars market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.



By Company


Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others

Segment by Application


Hospital
Retail Pharmacy
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Innovative Biologics and Biosimilars definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Innovative Biologics and Biosimilars companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Innovative Biologics and Biosimilars in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Innovative Biologics and Biosimilars revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions

Table of Content

1 Study Coverage
1.1 Innovative Biologics and Biosimilars Product Introduction
1.2 Global Innovative Biologics and Biosimilars Outlook 2018 VS 2024 VS 2034
1.2.1 Global Innovative Biologics and Biosimilars Market Size for the Year 2018-2034
1.2.2 United States Innovative Biologics and Biosimilars Market Size for the Year 2018-2034
1.3 Innovative Biologics and Biosimilars Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.3.1 The Market Share of United States Innovative Biologics and Biosimilars in Global, 2018 VS 2024 VS 2034
1.3.2 The Growth Rate of Innovative Biologics and Biosimilars Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.4 Innovative Biologics and Biosimilars Market Dynamics
1.4.1 Innovative Biologics and Biosimilars Industry Trends
1.4.2 Innovative Biologics and Biosimilars Market Drivers
1.4.3 Innovative Biologics and Biosimilars Market Challenges
1.4.4 Innovative Biologics and Biosimilars Market Restraints
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Innovative Biologics and Biosimilars by Type
2.1 Innovative Biologics and Biosimilars Market Segment by Type
2.1.1 Monoclonal Antibodies
2.1.2 Interferon
2.1.3 Insulin
2.1.4 Vaccines
2.1.5 Others
2.2 Global Innovative Biologics and Biosimilars Market Size by Type (2018, 2024 & 2034)
2.3 Global Innovative Biologics and Biosimilars Market Size by Type (2018-2034)
2.4 United States Innovative Biologics and Biosimilars Market Size by Type (2018, 2024 & 2034)
2.5 United States Innovative Biologics and Biosimilars Market Size by Type (2018-2034)
3 Innovative Biologics and Biosimilars by Application
3.1 Innovative Biologics and Biosimilars Market Segment by Application
3.1.1 Hospital
3.1.2 Retail Pharmacy
3.1.3 Other
3.2 Global Innovative Biologics and Biosimilars Market Size by Application (2018, 2024 & 2034)
3.3 Global Innovative Biologics and Biosimilars Market Size by Application (2018-2034)
3.4 United States Innovative Biologics and Biosimilars Market Size by Application (2018, 2024 & 2034)
3.5 United States Innovative Biologics and Biosimilars Market Size by Application (2018-2034)
4 Global Innovative Biologics and Biosimilars Competitor Landscape by Company
4.1 Global Innovative Biologics and Biosimilars Market Size by Company
4.1.1 Global Key Companies of Innovative Biologics and Biosimilars, Ranked by Revenue (2024)
4.1.2 Global Innovative Biologics and Biosimilars Revenue by Player (2018-2023)
4.2 Global Innovative Biologics and Biosimilars Concentration Ratio (CR)
4.2.1 Innovative Biologics and Biosimilars Market Concentration Ratio (CR) (2018-2023)
4.2.2 Global Top 5 and Top 10 Largest Companies of Innovative Biologics and Biosimilars in 2024
4.2.3 Global Innovative Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Players of Innovative Biologics and Biosimilars Head office and Area Served
4.4 Global Key Players of Innovative Biologics and Biosimilars, Product and Application
4.5 Global Key Players of Innovative Biologics and Biosimilars, Date of Enter into This Industry
4.6 Companies Mergers & Acquisitions, Expansion Plans
4.7 United States Innovative Biologics and Biosimilars Market Size by Company
4.7.1 Key Players of Innovative Biologics and Biosimilars in United States, Ranked by Revenue (2024)
4.7.2 United States Innovative Biologics and Biosimilars Revenue by Players (2021, 2024 & 2023)
5 Global Innovative Biologics and Biosimilars Market Size by Region
5.1 Global Innovative Biologics and Biosimilars Market Size by Region: 2018 VS 2024 VS 2034
5.2 Global Innovative Biologics and Biosimilars Market Size by Region (2018-2034)
5.2.1 Global Innovative Biologics and Biosimilars Market Size by Region: 2018-2023
5.2.2 Global Innovative Biologics and Biosimilars Market Size by Region (2024-2034)
6 Americas
6.1 Americas Innovative Biologics and Biosimilars Market Size YoY Growth 2018-2034
6.2 Americas Innovative Biologics and Biosimilars Market Size by Type
6.2.1 Americas Innovative Biologics and Biosimilars Market Size by Type (2018-2023)
6.2.2 Americas Innovative Biologics and Biosimilars Market Size by Type (2024-2034)
6.2.3 Americas Innovative Biologics and Biosimilars Market Share by Type (2018-2034)
6.3 Americas Innovative Biologics and Biosimilars Market Size by Application
6.3.1 Americas Innovative Biologics and Biosimilars Market Size by Application (2018-2023)
6.3.2 Americas Innovative Biologics and Biosimilars Market Size by Application (2024-2034)
6.3.3 Americas Innovative Biologics and Biosimilars Market Share by Application (2018-2034)
6.4 Americas Innovative Biologics and Biosimilars Market Facts & Figures by Country (2018, 2024 & 2034)
6.4.1 United States
6.4.2 Canada
6.4.3 Mexico
6.4.4 Brazil
7 EMEA
7.1 EMEA Innovative Biologics and Biosimilars Market Size YoY Growth 2018-2034
7.2 EMEA Innovative Biologics and Biosimilars Market Size by Type
7.2.1 EMEA Innovative Biologics and Biosimilars Market Size by Type (2018-2023)
7.2.2 EMEA Innovative Biologics and Biosimilars Market Size by Type (2024-2034)
7.2.3 EMEA Innovative Biologics and Biosimilars Market Share by Type (2018-2034)
7.3 EMEA Innovative Biologics and Biosimilars Market Size by Application
7.3.1 EMEA Innovative Biologics and Biosimilars Market Size by Application (2018-2023)
7.3.2 EMEA Innovative Biologics and Biosimilars Market Size by Application (2024-2034)
7.3.3 EMEA Innovative Biologics and Biosimilars Market Share by Application (2018-2034)
7.4 EMEA Innovative Biologics and Biosimilars Market Facts & Figures by Country (2018, 2024 & 2034)
7.4.1 Europe
7.4.2 Middle East
7.4.3 Africa
8 China
8.1 China Innovative Biologics and Biosimilars Market Size YoY Growth 2018-2034
8.2 China Innovative Biologics and Biosimilars Market Size by Type
8.2.1 China Innovative Biologics and Biosimilars Market Size by Type (2018-2023)
8.2.2 China Innovative Biologics and Biosimilars Market Size by Type (2024-2034)
8.2.3 China Innovative Biologics and Biosimilars Market Share by Type (2018-2034)
8.3 China Innovative Biologics and Biosimilars Market Size by Application
8.3.1 China Innovative Biologics and Biosimilars Market Size by Application (2018-2023)
8.3.2 China Innovative Biologics and Biosimilars Market Size by Application (2024-2034)
8.3.3 China Innovative Biologics and Biosimilars Market Share by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Innovative Biologics and Biosimilars Market Size YoY Growth 2018-2034
9.2 APAC Innovative Biologics and Biosimilars Market Size by Type
9.2.1 APAC Innovative Biologics and Biosimilars Market Size by Type (2018-2023)
9.2.2 APAC Innovative Biologics and Biosimilars Market Size by Type (2024-2034)
9.2.3 APAC Innovative Biologics and Biosimilars Market Share by Type (2018-2034)
9.3 APAC Innovative Biologics and Biosimilars Market Size by Application
9.3.1 APAC Innovative Biologics and Biosimilars Market Size by Application (2018-2023)
9.3.2 APAC Innovative Biologics and Biosimilars Market Size by Application (2024-2034)
9.3.3 APAC Innovative Biologics and Biosimilars Market Share by Application (2018-2034)
9.4 APAC Innovative Biologics and Biosimilars Market Facts & Figures by Country (2018, 2024 & 2034)
9.4.1 Japan
9.4.2 South Korea
9.4.3 China Taiwan
9.4.4 Southeast Asia
9.4.5 India
10 Key Players Profiles
10.1 Roche
10.1.1 Roche Company Details
10.1.2 Roche Business Overview
10.1.3 Roche Innovative Biologics and Biosimilars Introduction
10.1.4 Roche Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.1.5 Roche Recent Development
10.2 Amgen
10.2.1 Amgen Company Details
10.2.2 Amgen Business Overview
10.2.3 Amgen Innovative Biologics and Biosimilars Introduction
10.2.4 Amgen Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.2.5 Amgen Recent Development
10.3 AbbVie
10.3.1 AbbVie Company Details
10.3.2 AbbVie Business Overview
10.3.3 AbbVie Innovative Biologics and Biosimilars Introduction
10.3.4 AbbVie Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.3.5 AbbVie Recent Development
10.4 Sanofi
10.4.1 Sanofi Company Details
10.4.2 Sanofi Business Overview
10.4.3 Sanofi Innovative Biologics and Biosimilars Introduction
10.4.4 Sanofi Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.4.5 Sanofi Recent Development
10.5 Johnson & Johnson
10.5.1 Johnson & Johnson Company Details
10.5.2 Johnson & Johnson Business Overview
10.5.3 Johnson & Johnson Innovative Biologics and Biosimilars Introduction
10.5.4 Johnson & Johnson Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.5.5 Johnson & Johnson Recent Development
10.6 Pfizer
10.6.1 Pfizer Company Details
10.6.2 Pfizer Business Overview
10.6.3 Pfizer Innovative Biologics and Biosimilars Introduction
10.6.4 Pfizer Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.6.5 Pfizer Recent Development
10.7 Novo Nordisk
10.7.1 Novo Nordisk Company Details
10.7.2 Novo Nordisk Business Overview
10.7.3 Novo Nordisk Innovative Biologics and Biosimilars Introduction
10.7.4 Novo Nordisk Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.7.5 Novo Nordisk Recent Development
10.8 Eli Lilly
10.8.1 Eli Lilly Company Details
10.8.2 Eli Lilly Business Overview
10.8.3 Eli Lilly Innovative Biologics and Biosimilars Introduction
10.8.4 Eli Lilly Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.8.5 Eli Lilly Recent Development
10.9 Novartis
10.9.1 Novartis Company Details
10.9.2 Novartis Business Overview
10.9.3 Novartis Innovative Biologics and Biosimilars Introduction
10.9.4 Novartis Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.9.5 Novartis Recent Development
10.10 Merck
10.10.1 Merck Company Details
10.10.2 Merck Business Overview
10.10.3 Merck Innovative Biologics and Biosimilars Introduction
10.10.4 Merck Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.10.5 Merck Recent Development
10.11 Biogen
10.11.1 Biogen Company Details
10.11.2 Biogen Business Overview
10.11.3 Biogen Innovative Biologics and Biosimilars Introduction
10.11.4 Biogen Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.11.5 Biogen Recent Development
10.12 Celltrion
10.12.1 Celltrion Company Details
10.12.2 Celltrion Business Overview
10.12.3 Celltrion Innovative Biologics and Biosimilars Introduction
10.12.4 Celltrion Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.12.5 Celltrion Recent Development
10.13 Sobi
10.13.1 Sobi Company Details
10.13.2 Sobi Business Overview
10.13.3 Sobi Innovative Biologics and Biosimilars Introduction
10.13.4 Sobi Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.13.5 Sobi Recent Development
10.14 3SBIO
10.14.1 3SBIO Company Details
10.14.2 3SBIO Business Overview
10.14.3 3SBIO Innovative Biologics and Biosimilars Introduction
10.14.4 3SBIO Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.14.5 3SBIO Recent Development
10.15 Changchun High Tech
10.15.1 Changchun High Tech Company Details
10.15.2 Changchun High Tech Business Overview
10.15.3 Changchun High Tech Innovative Biologics and Biosimilars Introduction
10.15.4 Changchun High Tech Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.15.5 Changchun High Tech Recent Development
10.16 Kanghong Pharma
10.16.1 Kanghong Pharma Company Details
10.16.2 Kanghong Pharma Business Overview
10.16.3 Kanghong Pharma Innovative Biologics and Biosimilars Introduction
10.16.4 Kanghong Pharma Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.16.5 Kanghong Pharma Recent Development
10.17 Innovent Biologics
10.17.1 Innovent Biologics Company Details
10.17.2 Innovent Biologics Business Overview
10.17.3 Innovent Biologics Innovative Biologics and Biosimilars Introduction
10.17.4 Innovent Biologics Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.17.5 Innovent Biologics Recent Development
10.18 Gan&Lee
10.18.1 Gan&Lee Company Details
10.18.2 Gan&Lee Business Overview
10.18.3 Gan&Lee Innovative Biologics and Biosimilars Introduction
10.18.4 Gan&Lee Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.18.5 Gan&Lee Recent Development
10.19 Tonghua Dongbao
10.19.1 Tonghua Dongbao Company Details
10.19.2 Tonghua Dongbao Business Overview
10.19.3 Tonghua Dongbao Innovative Biologics and Biosimilars Introduction
10.19.4 Tonghua Dongbao Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.19.5 Tonghua Dongbao Recent Development
10.20 United Laboratory
10.20.1 United Laboratory Company Details
10.20.2 United Laboratory Business Overview
10.20.3 United Laboratory Innovative Biologics and Biosimilars Introduction
10.20.4 United Laboratory Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
10.20.5 United Laboratory Recent Development
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details

List of Figure

List of Tables
Table 1. Innovative Biologics and Biosimilars Market Size United States VS Global, CAGR (2018 VS 2024 VS 2034)
Table 2. Innovative Biologics and Biosimilars Market Trends
Table 3. Innovative Biologics and Biosimilars Market Drivers
Table 4. Innovative Biologics and Biosimilars Market Challenges
Table 5. Innovative Biologics and Biosimilars Market Restraints
Table 6. Global Innovative Biologics and Biosimilars Market Size by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. United States Innovative Biologics and Biosimilars Market Size by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Innovative Biologics and Biosimilars Market Size by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. United States Innovative Biologics and Biosimilars Market Size by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Key Companies of Innovative Biologics and Biosimilars, Ranked by Revenue (2024) & (US$ Million)
Table 11. Global Innovative Biologics and Biosimilars Revenue by Player, (US$ Million), 2018-2023
Table 12. Global Innovative Biologics and Biosimilars Revenue Share by Player, 2018-2023
Table 13. Global Innovative Biologics and Biosimilars Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Innovative Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Innovative Biologics and Biosimilars as of 2024)
Table 15. Global Key Players of Innovative Biologics and Biosimilars, Headquarters and Area Served
Table 16. Global Key Players of Innovative Biologics and Biosimilars, Product and Application
Table 17. Global Key Players of Innovative Biologics and Biosimilars, Date of Enter into This Industry
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Key Players of Innovative Biologics and Biosimilars in United States, Ranked by Revenue (2024) & (US$ Million)
Table 20. United States Innovative Biologics and Biosimilars Revenue by Players, (US$ Million), 2021, 2024 & 2023
Table 21. United States Innovative Biologics and Biosimilars Revenue Share by Players, 2021, 2024 & 2023
Table 22. Global Innovative Biologics and Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 23. Global Innovative Biologics and Biosimilars Market Size by Region (2018-2023) & (US$ Million)
Table 24. Global Innovative Biologics and Biosimilars Market Size Forecast by Region (2024-2034) & (US$ Million)
Table 25. Americas Innovative Biologics and Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 26. Americas Innovative Biologics and Biosimilars Market Size by Type (2024-2034) & (US$ Million)
Table 27. Americas Innovative Biologics and Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 28. Americas Innovative Biologics and Biosimilars Market Size by Application (2024-2034) & (US$ Million)
Table 29. Americas Innovative Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 30. Americas Innovative Biologics and Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 31. Americas Innovative Biologics and Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 32. EMEA Innovative Biologics and Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 33. EMEA Innovative Biologics and Biosimilars Market Size by Type (2024-2034) & (US$ Million)
Table 34. EMEA Innovative Biologics and Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 35. EMEA Innovative Biologics and Biosimilars Market Size by Application (2024-2034) & (US$ Million)
Table 36. EMEA Innovative Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 37. EMEA Innovative Biologics and Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 38. EMEA Innovative Biologics and Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 39. China Innovative Biologics and Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 40. China Innovative Biologics and Biosimilars Market Size by Type (2024-2034) & (US$ Million)
Table 41. China Innovative Biologics and Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 42. China Innovative Biologics and Biosimilars Market Size by Application (2024-2034) & (US$ Million)
Table 43. China Innovative Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 44. APAC Innovative Biologics and Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 45. APAC Innovative Biologics and Biosimilars Market Size by Type (2024-2034) & (US$ Million)
Table 46. APAC Innovative Biologics and Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 47. APAC Innovative Biologics and Biosimilars Market Size by Application (2024-2034) & (US$ Million)
Table 48. APAC Innovative Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 49. APAC Innovative Biologics and Biosimilars Market Size by Region (2018-2023) & (US$ Million)
Table 50. APAC Innovative Biologics and Biosimilars Market Size by Region (2024-2034) & (US$ Million)
Table 51. Roche Company Details
Table 52. Roche Business Overview
Table 53. Roche Innovative Biologics and Biosimilars Product
Table 54. Roche Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 55. Roche Recent Development
Table 56. Amgen Company Details
Table 57. Amgen Business Overview
Table 58. Amgen Innovative Biologics and Biosimilars Product
Table 59. Amgen Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 60. Amgen Recent Development
Table 61. AbbVie Company Details
Table 62. AbbVie Business Overview
Table 63. AbbVie Innovative Biologics and Biosimilars Product
Table 64. AbbVie Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 65. AbbVie Recent Development
Table 66. Sanofi Company Details
Table 67. Sanofi Business Overview
Table 68. Sanofi Innovative Biologics and Biosimilars Product
Table 69. Sanofi Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 70. Sanofi Recent Development
Table 71. Johnson & Johnson Company Details
Table 72. Johnson & Johnson Business Overview
Table 73. Johnson & Johnson Innovative Biologics and Biosimilars Product
Table 74. Johnson & Johnson Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 75. Johnson & Johnson Recent Development
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Innovative Biologics and Biosimilars Product
Table 79. Pfizer Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Novo Nordisk Company Details
Table 82. Novo Nordisk Business Overview
Table 83. Novo Nordisk Innovative Biologics and Biosimilars Product
Table 84. Novo Nordisk Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 85. Novo Nordisk Recent Development
Table 86. Eli Lilly Company Details
Table 87. Eli Lilly Business Overview
Table 88. Eli Lilly Innovative Biologics and Biosimilars Product
Table 89. Eli Lilly Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 90. Eli Lilly Recent Development
Table 91. Novartis Company Details
Table 92. Novartis Business Overview
Table 93. Novartis Innovative Biologics and Biosimilars Product
Table 94. Novartis Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 95. Novartis Recent Development
Table 96. Merck Company Details
Table 97. Merck Business Overview
Table 98. Merck Innovative Biologics and Biosimilars Product
Table 99. Merck Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 100. Merck Recent Development
Table 101. Biogen Company Details
Table 102. Biogen Business Overview
Table 103. Biogen Innovative Biologics and Biosimilars Product
Table 104. Biogen Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 105. Biogen Recent Development
Table 106. Celltrion Company Details
Table 107. Celltrion Business Overview
Table 108. Celltrion Innovative Biologics and Biosimilars Product
Table 109. Celltrion Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 110. Celltrion Recent Development
Table 111. Sobi Company Details
Table 112. Sobi Business Overview
Table 113. Sobi Innovative Biologics and Biosimilars Product
Table 114. Sobi Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 115. Sobi Recent Development
Table 116. 3SBIO Company Details
Table 117. 3SBIO Business Overview
Table 118. 3SBIO Innovative Biologics and Biosimilars Product
Table 119. 3SBIO Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 120. 3SBIO Recent Development
Table 121. Changchun High Tech Company Details
Table 122. Changchun High Tech Business Overview
Table 123. Changchun High Tech Innovative Biologics and Biosimilars Product
Table 124. Changchun High Tech Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 125. Changchun High Tech Recent Development
Table 126. Kanghong Pharma Company Details
Table 127. Kanghong Pharma Business Overview
Table 128. Kanghong Pharma Innovative Biologics and Biosimilars Product
Table 129. Kanghong Pharma Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 130. Kanghong Pharma Recent Development
Table 131. Innovent Biologics Company Details
Table 132. Innovent Biologics Business Overview
Table 133. Innovent Biologics Innovative Biologics and Biosimilars Product
Table 134. Innovent Biologics Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 135. Innovent Biologics Recent Development
Table 136. Gan&Lee Company Details
Table 137. Gan&Lee Business Overview
Table 138. Gan&Lee Innovative Biologics and Biosimilars Product
Table 139. Gan&Lee Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 140. Gan&Lee Recent Development
Table 141. Tonghua Dongbao Company Details
Table 142. Tonghua Dongbao Business Overview
Table 143. Tonghua Dongbao Innovative Biologics and Biosimilars Product
Table 144. Tonghua Dongbao Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 145. Tonghua Dongbao Recent Development
Table 146. United Laboratory Company Details
Table 147. United Laboratory Business Overview
Table 148. United Laboratory Innovative Biologics and Biosimilars Product
Table 149. United Laboratory Revenue in Innovative Biologics and Biosimilars Business (2018-2023) & (US$ Million)
Table 150. United Laboratory Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Innovative Biologics and Biosimilars Product Picture
Figure 2. Global Innovative Biologics and Biosimilars Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 3. Global Innovative Biologics and Biosimilars Market Size 2018-2034 (US$ Million)
Figure 4. United States Innovative Biologics and Biosimilars Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 5. United States Innovative Biologics and Biosimilars Market Size 2018-2034 (US$ Million)
Figure 6. United States Innovative Biologics and Biosimilars Market Share in Global 2018-2034
Figure 7. Innovative Biologics and Biosimilars Report Years Considered
Figure 8. Product Picture of Monoclonal Antibodies
Figure 9. Product Picture of Interferon
Figure 10. Product Picture of Insulin
Figure 11. Product Picture of Vaccines
Figure 12. Product Picture of Others
Figure 13. Global Innovative Biologics and Biosimilars Market Share by Type in 2024 & 2034
Figure 14. Global Innovative Biologics and Biosimilars Market Size by Type (2018-2034) & (US$ Million)
Figure 15. Global Innovative Biologics and Biosimilars Market Share by Type (2018-2034)
Figure 16. United States Innovative Biologics and Biosimilars Market Share by Type in 2024 & 2034
Figure 17. United States Innovative Biologics and Biosimilars Market Size by Type (2018-2034) & (US$ Million)
Figure 18. United States Innovative Biologics and Biosimilars Market Share by Type (2018-2034)
Figure 19. Product Picture of Hospital
Figure 20. Product Picture of Retail Pharmacy
Figure 21. Product Picture of Other
Figure 22. Global Innovative Biologics and Biosimilars Market Share by Application in 2024 & 2034
Figure 23. Global Innovative Biologics and Biosimilars Market Size by Application (2018-2034) & (US$ Million)
Figure 24. Global Innovative Biologics and Biosimilars Market Share by Application (2018-2034)
Figure 25. United States Innovative Biologics and Biosimilars Market Share by Application in 2024 & 2034
Figure 26. United States Innovative Biologics and Biosimilars Market Size by Application (2018-2034) & (US$ Million)
Figure 27. United States Innovative Biologics and Biosimilars Market Share by Application (2018-2034)
Figure 28. The Top 5 and 10 Largest Companies of Innovative Biologics and Biosimilars in the World: Market Share by Innovative Biologics and Biosimilars Revenue in 2024
Figure 29. Global Innovative Biologics and Biosimilars Market Size Market Share by Region: 2018 VS 2024 VS 2034
Figure 30. Global Innovative Biologics and Biosimilars Market Share by Region (2018-2034)
Figure 31. Americas Innovative Biologics and Biosimilars Market Size Growth Rate 2018-2034 (US$ Million)
Figure 32. Americas Innovative Biologics and Biosimilars Market Share by Type (2018-2034)
Figure 33. Americas Innovative Biologics and Biosimilars Market Share by Application (2018-2034)
Figure 34. United States Innovative Biologics and Biosimilars Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 35. Canada Innovative Biologics and Biosimilars Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 36. Mexico Innovative Biologics and Biosimilars Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 37. Brazil Innovative Biologics and Biosimilars Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 38. EMEA Innovative Biologics and Biosimilars Market Size Growth Rate 2018-2034 (US$ Million)
Figure 39. EMEA Innovative Biologics and Biosimilars Market Share by Type (2018-2034)
Figure 40. EMEA Innovative Biologics and Biosimilars Market Share by Application (2018-2034)
Figure 41. Europe Innovative Biologics and Biosimilars Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 42. Middle East Innovative Biologics and Biosimilars Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 43. Africa Innovative Biologics and Biosimilars Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 44. China Innovative Biologics and Biosimilars Market Size Growth Rate 2018-2034 (US$ Million)
Figure 45. China Innovative Biologics and Biosimilars Market Share by Type (2018-2034)
Figure 46. China Innovative Biologics and Biosimilars Market Share by Application (2018-2034)
Figure 47. APAC Innovative Biologics and Biosimilars Market Size Growth Rate 2018-2034 (US$ Million)
Figure 48. APAC Innovative Biologics and Biosimilars Market Share by Type (2018-2034)
Figure 49. APAC Innovative Biologics and Biosimilars Market Share by Application (2018-2034)
Figure 50. Japan Innovative Biologics and Biosimilars Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 51. South Korea Innovative Biologics and Biosimilars Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 52. China Taiwan Innovative Biologics and Biosimilars Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 53. Southeast Asia Innovative Biologics and Biosimilars Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 54. India Innovative Biologics and Biosimilars Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 55. Roche Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 56. Amgen Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 57. AbbVie Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 58. Sanofi Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 59. Johnson & Johnson Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 60. Pfizer Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 61. Novo Nordisk Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 62. Eli Lilly Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 63. Novartis Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 64. Merck Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 65. Biogen Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 66. Celltrion Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 67. Sobi Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 68. 3SBIO Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 69. Changchun High Tech Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 70. Kanghong Pharma Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 71. Innovent Biologics Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 72. Gan&Lee Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 73. Tonghua Dongbao Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 74. United Laboratory Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2018-2023)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed